Versatile, Tunable Biomedical Nanoparticle Technology
Successful development of the first liposome based nanoparticle therapeutic, Doxil® marketed by J&J, provides proof of clinical benefit possible by nanoparticle drug delivery technology. AparnaBio developed polymer based nanoparticles that solve major biomedical problems, including a capability to tune drug loading for diverse cargos, NanoElectroPlex™ (NEP™), that can be used for many important classes of therapeutic agents as well as imaging agents, from revolutionary RNAi selective gene inhibitors to proteins to anionic small molecules, and their combinations. The NEP™ technology can be tuned to match a wide range of cargo by adjusting the polymeric carrier ionic charge density and branching, illustrated below. AparnaBio also has achieved surface ligand decoration of NEP™ for tissue selective localization. These powerful capabilities fill major needs, and are based on versatile polymer and macromolecule classes, including biodegradable polyamides, and well developed conjugation chemistry. NEP™ has been optimized in first efforts for nucleic acids, addressing one of the most difficult challenges for these highly charged macromolecules: in vivo intracellular delivery. A non-biodegradable form of NEP™ has been used to construct the InVivoPlex® and InVitroPlex® reagent families, and a biodegradable form with characteristics critical for clinical applications, such as low cytokine induction or other off-target effects has been developed for clinical applications.
In vitro siRNA inhibition of endogenous gene by NanoElectroPlex™ in tumor cell lines. Tumor cells were reverse-transfected for 24 hr in a 24 well plate with 5 µg/well siRNA formulated in NanoElectroPlex™ and the media replaced every 24 hr. After 72 hr supernatant was removed and assayed for VEGF protein by ELISA. The cells were lysed for total cell protein assay.